1 in 10 TAVR Procedures Done Off-Label Despite early risks vs on-label use, 'acceptable results' cited from registry
Off-label transcatheter aortic valve replacement (TAVR) procedures were associated with more in-hospital adverse events and 30-day mortality, although 1 year outcomes were similar to on-label use, the national Transcatheter Valve Therapy (TVT) Registry showed.